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proportion of them. The method of sample selection was not reported. Each case was matched with five serum samples from the pool of pregnancies with normal karyotype (controls). The following variables were used for matching: recruitment centre; completed week of gestation; month of enrolment; and maternal age. The authors noted that 4 of the control samples selected were not available. The authors reported that possible biases in sample selection were eliminated by the fact that all pregnancies were karyotyped in the second trimester, and that the indications for amniocentesis did not include abnormal screening results.
Study design
This was a multi-centre, case-control study. The number of centres involved was not reported. The duration of followup or loss to follow-up was not reported. The assessment of outcomes was blinded. Assays were performed without knowledge of whether the sample was from a case or control pregnancy.
Analysis of effectiveness
The method of analysis of the clinical study was not reported. The primary outcome used in the analysis was the screening performance of dimeric inhibin A (alone or in combination with other serum markers) to detect Down's syndrome. Dimeric inhibin A was measured in duplicate using a solid phase sandwich enzyme linked immunosorbent assay. The methods for measuring the other serum markers (alpha-fetoprotein, unconjugated oestriol, and human chorionic gonadotrophin and its free beta subunit) were not reported in this study. The case and control groups differed with respect to gestational age. Gestational age specific median values for dimeric inhibin A were computed using measurements from the controls. Individual assay measurements were then converted to multiples of the median (MOM) and adjusted for maternal weight using a published method. This method was not reported.
Effectiveness results
The effectiveness results were as follows:
At a 5% false positive rate, the combination of maternal age and dimeric inhibin A identified 52% of Down's syndrome pregnancies.
Adding aplha-fetoprotein increased the detection rate to 68%.
A triple test of aplha-fetoprotein, unconjugated oestriol and dimeric inhibin A increased the detection rate to 73%.
A four-marker test had the highest detection rate of 75%.
The false positive rate for the triple test at a 70% detection rate was 4.2%.
The four-marker test had a false positive rate of 3.4%.
Clinical conclusions
The authors concluded that this study confirmed the results of previous studies indicating that dimeric inhibin A is among the best second trimester maternal serum markers for the detection of Down's syndrome. In contrast with other serum markers the levels of dimeric inhibin A do not vary with gestational age during the second trimester.
Modelling
A published model, that was not described, was used to estimate the reliability of Down's syndrome screening performance for dimeric inhibin A, both alone and in combination with other serum markers.
Measure of benefits used in the economic analysis
No summary measure of benefit was reported in this study. The outcomes were reported in a disaggregated way and as such, a cost-consequence analysis was performed. dimeric inhibin A, either alone or in combination with other serum markers, does reflect screening options for the detection of Down's syndrome in the UK.
Validity of estimate of measure of effectiveness
The study assessed the effectiveness of dimeric inhibin A in terms of detecting Down's syndrome in maternal serum samples from Down's syndrome pregnancies. These were compared with serum samples from unaffected pregnancies. The serum samples for the study were selected from a dataset of samples collected for a different multi-centre cohort study. The authors reported the advantages of the dataset to be: all pregnancies were karyotyped in the second trimester, eliminating the possibility of biased sampling; the indications for diagnostic testing in the original study did not include abnormal screening test results (which would have biased the sample and estimation of analyte levels in the cases and controls); the other serum marker measurements were made on fresh samples over the a two year period when the samples were collected; and gestational dating based on last menstrual period and biparietal diameter data allowed accurate direct comparison of screening performance.
However, the authors did not report sufficient information about the study sample, method of selection, the power to detect statistically significant differences with the sample size used or methods of measurement and analysis. This means that it is not possible to assess either the level of uncertainty of the results or whether the study sample was representative of the study population.
Validity of estimate of measure of benefit
This study made no assessment of benefit from adding dimeric inhibin A to patient health gain. The analysis was therefore a cost-consequences study.
Validity of estimate of costs
No information was provided on the types or quantities of resource use or the data source for unit costs. This study presented an exploratory analysis of costs to determine the maximum acceptable cost of additional testing. This was set equal to the savings from reduced costs of diagnosis using amniocentesis.
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